Aromatase inhibitors (AIs) are routinely used in treating estrogen receptor (ER)-positive breast cancer in postmenopausal women and are effective in reducing the recurrence of metastatic hormone-sensitive breast cancer. The gene discussed is ESR1; the disease is breast cancer.